Small molecule · developed by Pharvaris Netherlands B.V.
Deucrictibant is an oral agent given as softgel capsules, an extended-release tablet, or a soft capsule, studied in acquired angioedema due to C1-inhibitor deficiency and in hereditary angioedema.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07266805 | Phase 3 | Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH) | Recruiting | PHVS |
| NCT05047185 | Phase 2 | Hereditary Angioedema | Terminated | PHVS |
| NCT07759141 | N/A | Hereditary Angioedema | Available | PHVS |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
C1 Esterase Inhibitor DeficiencyC1 Inhibitor DeficiencyHereditary AngioedemaHereditary Angioedema - Type 1Hereditary Angioedema - Type 2Hereditary Angioedema AttackHereditary Angioedema Type IHereditary Angioedema Type IIHereditary Angioedema Types I and IIHereditary Angioedema With C1 Esterase Inhibitor Deficiency
Updated Nov 15, 2026. Something wrong or missing? Report it on the PHVS page.
See PHVS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
PHVS catalysts and pipeline →